Biosynexus

Biosynexus Incorporated is a biopharmaceutical company developing pagibaximab, a monoclonal antibody for the prevention of staphylococcal sepsis in very low birth weight (VLBW) infants within the neonatal intensive care unit (NICU) setting. The company also has two additional product candidates: lysostaphin for the treatment of life-threatening staphylococcal infections and nisin for the treatment of severe skin infections.Biosynexus’s mission is to bring products to market for the prevention and treatment of bacterial infections, with a focus on preventing staphylococcal infections in VLBW infants.